Publications by authors named "Gillian F Cropp"

Claim this Profile
A
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors.
J Paul Monk, Miguel Villalona-Calero, Joe Larkin, Greg Otterson, David S Spriggs, Gillian F Cropp

Invest New Drugs· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.
Elaine T Lam, Sanjay Goel, Larry J Schaaf, Gillian F Cropp, Alison L Hannah

Cancer Chemother Pharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Shanu Modi, Alison T Stopeck, Michael S Gordon, David Mendelson, David B Solit, Gillian F Cropp

J Clin Oncol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Albert Craig Lockhart, Gillian F Cropp, Jordan D Berlin, Edwin Donnelly, Robert D Schumaker

Am J Clin Oncol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Bart C Kuenen, Lee Rosen, Egbert F Smit, Mandy R N Parson, Marcel Levi, Gillian F Cropp

J Clin Oncol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis